



COLORADO

Department of Health Care
Policy & Financing

AGENDA

Pharmaceuticals & Therapeutics Committee

Department of Health Care Policy & Financing

Zoom Webinar Registration: TBA
Tuesday, October 8, 2024, 1:00-5:00 P.M.

1. Committee Member Introductions

2. Unfinished Business and General Orders

Approval of minutes from July 9, 2024 P&T meeting
Updates from July 9, 2024 P&T Meeting

3. New Business

Updates from the Prior Authorization Call Center
Announcement of term expirations and open positions for January 2025

4. Drug Classes Up for Review

Review of Human Immunodeficiency Virus (HIV) Treatments

Review of Immune Globulins

Review of Methotrexate Products

Review of Targeted Immune Modulators

Asthma, Other Agents

Review of Respiratory Agents

Inhaled Beta2 Agonists (Short & Long-Acting), Phosphodiesterase Inhibitors (PDEIs)

Mass review drug classes:

- Antibiotics, Inhaled
- Antiherpetic Agents - Oral, Topical
- Fluoroquinolones, Oral
- Hepatitis C Virus Treatments
 - Direct Acting Antivirals, Other Agents, Ribavirin
- Antihistamines
 - Newer Generation, Antihistamine/Decongestant Combinations
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Epinephrine Products
- Newer Hereditary Angioedema (HAE) Products
- Respiratory Agents



- Inhaled Anticholinergics & Combinations, Inhaled Corticosteroids & Combinations

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jessica.czechowski@primetherapeutics.com and carbon copy Greg Miller, PDL & Clinical Strategy Pharmacist, greg.l.miller@state.co.us. Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **October 1, 2024 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: January 07, 2025.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

